Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC

Bibliography

• 1  Tsubochi H, Nobuyuki S, Hiyama M et al.: Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in non-small cell lung cancer. Ann. Thorac. Surg.82(4),1198–1204 (2006).
  MedlineGoogle Scholar
• 2  Riedl K, Kostyantyn K, Pold M et al.: Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resistance Updates.7,169–184 (2004).
  Medline CASGoogle Scholar
• 3  Dy GK, Adjei AA: Novel targets for lung cancer therapy: part I. J. Clin. Oncol.20,2881–2894 (2002).
  Medline CASGoogle Scholar
• 4  Dy GK, Adjei AA: Novel targets for lung cancer therapy: part II. J. Clin. Oncol.20,3016–3028 (2002).
  Medline CASGoogle Scholar
• 5  Dubinett S, Sharma S, Huang M, Dohadwala M, Pold M, Mao J: Cyclooxygenase-2 in lung cancer. Progressive Experimental Tumor Reearch. Bertino JR (Ed.), Basel Karger. Basel, Switzerland 138–162 (2003).
  Google Scholar
• 6  Dannenberg AJ, Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell.4,431–436 (2003).
  Medline CASGoogle Scholar
• 7  Herschman H: Review: prostaglandin synthase 2. Biochim. Biophys. Acta1299,125–140 (1996).
  MedlineGoogle Scholar
• 8  Soslow RA, Dannenberg AJ, Rush D et al.: Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer89,2637–2645 (2000).
  Medline CASGoogle Scholar
• 9  Yip-Schneider MT, Barnard DS, Billings SD et al.: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis21,139–146 (2000).
  Medline CASGoogle Scholar
• 10  Kirschenbaum A, Liu X, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology58,127–131 (2001).
  Medline CASGoogle Scholar
• 11  Fujita T, Matsui M, Takaku K et al.: Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res.58,4823–4826 (1998).
  Medline CASGoogle Scholar
• 12  Shamma A, Yamamoto H, Doki Y et al.: Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res.6,1229–1238 (2000).
  Medline CASGoogle Scholar
• 13  Chan G, Boyle JO, Yang EK et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res.59,991–994 (1999).
  Medline CASGoogle Scholar
• 14  Huang M, Stolina M, Sharma S et al.: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res.58>, 1208 (1998).
  Medline CASGoogle Scholar
• 15  Hida T, Yatabe Y, Achiwa H et al.: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res.58,3761–3764 (1998).
  Medline CASGoogle Scholar
• 16  Wolff H, Saukkonen K, Anttila S et al.: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res.58,4997–5001 (1998).
  Medline CASGoogle Scholar
• 17  Hosomi Y, Yokose T, Hirose Y et al.: Increased cyclooxygenase 2 (Cox-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer30,73–81 (2000).
  Medline CASGoogle Scholar
• 18  Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell83,493–501 (1995).
  Medline CASGoogle Scholar
• 19  Krysan K, Dalwadi H, Sharma S et al.: Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res.64,6359–6362 (2004).
  Medline CASGoogle Scholar
• 20  Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev.19,19–27 (2000).
  Medline CASGoogle Scholar
• 21  Leahy K, Koki A, Masferrer J: Role of cyclooxygenases in angiogenesis. Curr. Med. Chem.7,1163–1170 (2000).
  Medline CASGoogle Scholar
• 22  Masferrer JL, Leahy KM, Koki AT: Role of cyclooxygenases in angiogenesis. Curr. Med. Chem.7,1163–1170 (2000).
  MedlineGoogle Scholar
• 23  Stolina M, Sharma S, Lin Y et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol.164,361–370 (2000).
  Medline CASGoogle Scholar
• 24  Baratelli F, Lin Y, Zhu L et al.: PGE2 incudes FOXP3 gene expression and T regulatory function in human CD4⁺ T cells. J. Immunol.175,1483–1490 (2005).
  Medline CASGoogle Scholar
• 25  Sheng H, Shao J, Washington MK et al.: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem.276,18075–18081 (2001).
  Medline CASGoogle Scholar
• 26  Dohadwala M, Luo J, Zhu L et al.: Non-small cell lung cancer cylooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem.276,20809–20812 (2001).
  Medline CASGoogle Scholar
• 27  Levesque AA, Eastman A: p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis28(1),13–20 (2007).
  Medline CASGoogle Scholar
• 28  Haupt S, Haupt Y: Importance of p53 for cancer onset and therapy. Anti-Cancer Drugs.17,725–732 (2006).
  Medline CASGoogle Scholar
• 29  Endl E, Gerdes J: The Ki-67 protein: fascinating forms and an unknown function. Exp. Cell Res.257,231–237 (2000).
  Medline CASGoogle Scholar
• 30  Campling BG, El-Deiry WS: Clinical implication of p53 in lung cancer. Mol. Biotechnol.24(2),141–156 (2003).
  Medline CASGoogle Scholar
• 31  Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J. Cell. Physiol.182,311–322 (2000).
  Medline CASGoogle Scholar
• 32  Achiwa H, Yatabe Y, Hida T et al.: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res.5,1001–1005 (1999).
  Medline CASGoogle Scholar
• 33  Brabender J, Park J, Metzger R et al.: Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg.235,440–443 (2002).
  MedlineGoogle Scholar
• 34  Hasturk S, Kemp B, Kalapurakal SK et al.: Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer94,1023–1031 (2002).
  Medline CASGoogle Scholar
• 35  Soslow RA, Dannenberg AJ, Rush D et al.: Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer89,2637–2645 (2000).
  Medline CASGoogle Scholar
• 36  Khuri FR, Wu H, Lee JJ et al.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res.7,861–867 (2001).
  Medline CASGoogle Scholar
• 37  Kim HS, Youm HR, Lee JS et al.: Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer42,163–170 (2003).
  MedlineGoogle Scholar
• 38  West H, Yaziji H, Giarrita S et al.: Cyclooxygenase-2 (Cox-2) overexpression by immunohistochemistry (IHC) is associated with more aggressive biologic behavior of non-small cell lung cancer (NSCLC) tumors. Proc. Am. Soc. Clin. Oncol.21,1235 (2002).
  Google Scholar
• 39  Campa D, Zienolddiny S, Maggini V et al.: Association of a common polymorphism in the cyclooxygenase-2 gene with risk of non-small cell lung cancer. Carcinogenesis25,229–235 2004).
  Medline CASGoogle Scholar
• 40  Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology5,138–146 (1994).
  Medline CASGoogle Scholar
• 41  Smith WL, deWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem.69,145–182 (2000).
  Medline CASGoogle Scholar
• 42  Subbaramaiah K, Altorki N, Chung WJ et al.: Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem.274,10911–10915 (1999).
  Medline CASGoogle Scholar
• 43  Subbaramaiah K, Telang N, Ramonetti JT et al.: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res.56,4424–4429 (1996).
  Medline CASGoogle Scholar
• 44  Bissonnette M, Khare S, von Lintig FC et al.: Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Cancer Res.60,4602–4609 (2000).
  Medline CASGoogle Scholar
• 45  Fujita M, Fukui H, Kusaka T et al.: Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J. Gastroenterol. Hepatol.15,1277–1281 (2000).
  Medline CASGoogle Scholar
• 46  Gilhooly E, Rose D: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int. J. Oncol.15,267–270 (1999).
  Medline CASGoogle Scholar
• 47  Krysan K, Reckamp KL, Dalwadi H et al.: PGE2 activates MAPK/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an EGF receptor-independent manner. Cancer Res.65,6275–6281 (2005).
  Medline CASGoogle Scholar
• 48  Reckamp KL, Krysan K, Morrow JD et al.: A Phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin. Cancer Res.12,3381–3388 (2006).
  Medline CASGoogle Scholar
• 49  Mao JT, Fishbein MC, Adams B et al.: Celecoxib decreases Ki-67 proliferative index in active smokers. Clin. Cancer Res.12,314–320 (2006).
  Medline CASGoogle Scholar
• 50  Mao JT, Cui X, Reckamp K et al.: Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin. Lung Cancer.7(1),30–39 (2005).
  Medline CASGoogle Scholar